Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you obtain a urinalysis for glucose testing for your patients on SGLT2 inhibitors to assess for medication adherence?
Answer from: at Community Practice
I do not do a UA solely for this purpose, but it helps to have one for other routine testing purposes that demonstrate the glucosuria.
Sign in or Register to read more
28588
Related Questions
How would you approach management of retroperitoneal fibrosis causing ureteral compression that has already caused irreversible loss of kidney function?
Would you avoid SGLT2 inhibitors in patients with nephrostomy tubes?
Do you use biomarkers to improve risk prediction in patients with ADPKD during early disease stages?
Do you prefer to simultaneously start an ACEi/ARB and SGLT2i or initiate one prior to the other in a patient with proteinuria secondary to diabetic kidney disease?
How do you choose between initiating long-term therapy with mTOR inhibitors versus opting for interventional treatments such as embolization or surgery in a patient with tuberous sclerosis, experiencing flank pain, and with renal angiomyolipomas larger than 4 cm?
Is it safe to use acarbose in patients with advanced chronic kidney disease?
Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?
How would you advise a CKD patient who asks about oral NSAIDs for management of chronic pain if they have a contraindication to taking acetaminophen?
Under what circumstances would you hold an ACE inhibitor or ARB prior to surgery in a patient with CKD?
Do you recommend temporarily holding SGLT2 inhibitors in patients with CKD who are undergoing CT imaging with intravenous contrast?